Recombinant human uteroglobin - Samaritan Pharmaceuticals

Drug Profile

Recombinant human uteroglobin - Samaritan Pharmaceuticals

Alternative Names: rUG

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Metastatin Pharmaceuticals
  • Class Anti-inflammatories; Recombinant proteins; Respiratory stimulants
  • Mechanism of Action Collagen receptor antagonists; Fibronectin receptor antagonists; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (SC)
  • 01 Mar 2007 Metastatin Pharmaceuticals has been acquired by Samaritan Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top